<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04045587</url>
  </required_header>
  <id_info>
    <org_study_id>H17 - 03052</org_study_id>
    <nct_id>NCT04045587</nct_id>
  </id_info>
  <brief_title>International Severe Asthma Registry: Canadian Cohort</brief_title>
  <acronym>ISAR</acronym>
  <official_title>International Severe Asthma Registry: Canadian Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The International Severe Asthma Registry is a global initiative looking to ensure that the
      care of people with severe asthma will continue to improve by collecting detailed information
      about the health and treatment of as many people with the disease as possible. The study will
      gather anonymized longitudinal real-life data for participants with severe asthma for five
      years. The purpose of the registry is to track the progress of participants and determine how
      well they are responding to treatment. Medical research using data from the registry will
      give the investigators a better understanding of severe asthma and help the investigators
      develop and improve the care and treatment for severe asthma participants. The Canadian
      cohort of the registry will collect information from Canadian participants with severe asthma
      across seven different sites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study staff will collect medical information through reviewing participant medical charts and
      interviewing participants about their health/asthma. The information collected includes birth
      date, gender, ethnicity, height/weight, body mass index, medical history (smoking history and
      exacerbation history), current and past asthma related medications, and any recent test
      results available pertaining to blood work, lung function, allergen skin prick, and imaging.
      This information will be collected at the baseline visit, and then once a year at a follow up
      visit, for five years (total of five visits).

      Participants will be assigned a unique study number to protect the confidentiality of their
      personal health care information. All study data will be de-identified and then stored in a
      secure information management system, hosted at the study sponsor, Optimum Patient Care
      Global Limited in Cambridge, United Kingdom. Participant identities will always be kept
      confidential and will not be included in any research that is published. Data collected
      across the Canadian sites will be used to find ways to improve asthma treatments in Canada,
      to report on current patterns of managing severe asthma in Canada, to identify different
      sub-groups of severe asthma, and to carry out various medical research to understand asthma
      better and develop new treatments.

      Research records and health or other source records may be inspected in the presence of the
      Principal Investigator or by representatives of the University of British Columbia's Clinical
      Research Ethics Board for the purpose of monitoring the research. No information or records
      that disclose participants' identities will be published without subject consent, nor will
      any information or records that disclose participants' identities be removed or released
      without subject consent unless required by law.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Blood eosinophil counts</measure>
    <time_frame>Past 12 months</time_frame>
    <description>10^9/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Immunoglobulin E (IgE) counts</measure>
    <time_frame>Past 12 months</time_frame>
    <description>kilo unit/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fractional exhaled nitric oxide level</measure>
    <time_frame>Past 12 months</time_frame>
    <description>parts per billion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Start and end dates of oral corticosteroid medication</measure>
    <time_frame>Prior to baseline visit</time_frame>
    <description>Day/Month/Year for start and end dates if available</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Asthma Control</measure>
    <time_frame>Past 4 weeks</time_frame>
    <description>Assessed through the Global Initiative for Asthma (GINA) Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Start and end dates of biologic medications such as anti-interleukin-5, anti-immunoglobulin E, or anti-interleukin-4 treatments (if relevant)</measure>
    <time_frame>Prior to baseline visit</time_frame>
    <description>Day/Month/Year for start and end dates if available</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reason for switching biologic medication (if relevant)</measure>
    <time_frame>Past 12 months</time_frame>
    <description>Options include: lack of clinical efficacy, side effects, biologic access restriction, and patient preference</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Start and end dates of all asthma related inhaled medications</measure>
    <time_frame>Prior to baseline visit</time_frame>
    <description>Day/Month/Year for start and end dates if available</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of asthma exacerbations requiring rescue steroids</measure>
    <time_frame>Past 12 months</time_frame>
    <description>Severe asthma exacerbations are defined as events that require urgent action (rescue steroids) by the participant and physician to prevent a serious outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of emergency room visits for asthma</measure>
    <time_frame>Past 12 months</time_frame>
    <description>Total number of visits</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of hospital admissions for asthma</measure>
    <time_frame>Past 12 months</time_frame>
    <description>Total number of admissions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spirometry test results for Forced Vital Capacity (FVC)</measure>
    <time_frame>Past 12 months</time_frame>
    <description>Pre- and post-bronchodilator FVC results in litres</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spirometry test results for Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Past 12 months</time_frame>
    <description>Pre- and post-bronchodilator FEV1 results in litres</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">714</enrollment>
  <condition>Severe Asthma</condition>
  <arm_group>
    <arm_group_label>Severe Asthma Participants</arm_group_label>
    <description>Participants with severe asthma classified at GINA Step 4 and uncontrolled in terms of their symptoms and exacerbations or GINA Step 5.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be selected from respirology/pulmonary clinics across Canada.
        Participants will be identified and recruited by the study investigators and study staff
        based on their clinical presentation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants 18 years or older

          -  Participants receiving treatment according to GINA Step 5 or uncontrolled in GINA Step
             4 (uncontrolled is defined as having severe asthma symptoms or frequent exacerbations)

        Exclusion Criteria:

        -Participants with mild to moderate asthma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark FitzGerald</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shelley Abercromby</last_name>
    <phone>(604) 875-4111</phone>
    <phone_ext>62500</phone_ext>
    <email>Shelley.Abercromby@vch.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisette Machado</last_name>
      <phone>(403) 220-3522</phone>
      <email>lmachado@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Patrick Mitchell</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Leigh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angie Hillaby</last_name>
      <phone>(780) 492-3741</phone>
      <email>ahillaby@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Mohit Bhutani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelley Abercromby</last_name>
      <phone>(604) 875-4111</phone>
      <phone_ext>62500</phone_ext>
      <email>Shelley.Abercromby@ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Mark FitzGerald</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Celine Bergeron</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shoshana Parker</last_name>
      <phone>(604) 682-2344</phone>
      <phone_ext>62492</phone_ext>
      <email>sparker@cheos.ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Delbert Dorscheid</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inspiration Research Limited</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T3A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jane Duke</last_name>
      <phone>(416) 944-9602</phone>
      <email>jduke@inspirationresearch.ca</email>
    </contact>
    <investigator>
      <last_name>Kenneth Chapman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cathy Fugere</last_name>
      <phone>(514) 934-1934</phone>
      <phone_ext>38936</phone_ext>
      <email>cathy.fugere@mail.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Ron Olivenstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Université Laval</name>
      <address>
        <city>Quebéc City</city>
        <state>Quebec</state>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Eve Boulay</last_name>
      <phone>(418) 656-8711</phone>
      <phone_ext>2617</phone_ext>
      <email>Marie-Eve.Boulay@criucpq.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Andréanne Côté</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louis-Philippe Boulet</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>August 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>August 2, 2019</last_update_submitted>
  <last_update_submitted_qc>August 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Mark Fitzgerald</investigator_full_name>
    <investigator_title>Dr. Mark FitzGerald</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

